{"schema_version":"1","generated_at":"2026-11-01T13:46:04.078Z","data_as_of":null,"url":"https://www.findmykol.com/kol/mark-geyer","json_url":"https://www.findmykol.com/kol/mark-geyer/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"mark-geyer","name":"Mark Geyer","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"New York","state":"NY","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1831482561"},"summary":"Mark Geyer is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"note":"Research metrics are not shown for this record: either no confident publication match for this name, or more than one clinician shares the matched author record."},"trials":{"count":3,"shown":3,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06017258","title":"A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia","phase":"PHASE1","status":"RECRUITING","role":"Overall official","sponsor":"Memorial Sloan Kettering Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT06017258","trial_url":"https://www.findmykol.com/trial/NCT06017258"},{"nct":"NCT04512716","title":"Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma","phase":"EARLY_PHASE1","status":"RECRUITING","role":"Overall official","sponsor":"Memorial Sloan Kettering Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT04512716","trial_url":"https://www.findmykol.com/trial/NCT04512716"},{"nct":"NCT04329325","title":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"Memorial Sloan Kettering Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT04329325","trial_url":"https://www.findmykol.com/trial/NCT04329325"}],"source":"trials"},"payments":{"company_count":7,"program_years":{"first":2021,"last":null},"rows_total":9,"shown":3,"withheld":6,"rows":[{"payer":"Takeda Pharmaceuticals U.S.A., Inc.","program_year":2025,"amount_usd":4258.01,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1831482561"},{"payer":"Amgen Inc.","program_year":2025,"amount_usd":1492.76,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1831482561"},{"payer":"Takeda Pharmaceuticals U.S.A., Inc.","program_year":2024,"amount_usd":10333.62,"payment_count":5,"source_url":"https://openpaymentsdata.cms.gov/search?query=1831482561"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1831482561","source":"payments"},"prescribing":{"data_year":2024,"areas_total":3,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":76.5,"classes_total":2,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":65.8,"drugs":[{"name":"Calquence","share_pct":25.6},{"name":"Bosulif","share_pct":20.9},{"name":"Brukinsa","share_pct":17.8},{"name":"Iclusig","share_pct":14.7},{"name":"Sprycel","share_pct":10.9},{"name":"Jaypirca","share_pct":10.1}],"max_beneficiaries":null},{"class":"BCL-2 Inhibitor","setting":"prescribed","share_pct":10.7,"drugs":[{"name":"Venclexta","share_pct":100}],"max_beneficiaries":null}]},{"area":"Anti-infectives","share_pct":15.3,"classes_total":2,"classes":[{"class":"Short-acting sulfonamides","setting":"prescribed","share_pct":8.7,"drugs":[{"name":"Sulfamethoxazole-Trimethoprim","share_pct":100}],"max_beneficiaries":null},{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":6.6,"drugs":[{"name":"Valacyclovir","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":8.2,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":8.2,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":60.3,"facility_pct":39.7},"source":"medicare"},"funding":{"award_count":2,"fiscal_years":{"first":2020,"last":2026},"rows_total":5,"shown":3,"withheld":2,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"R01CA291796","title":"Development of chimeric antigen receptor T cells targeting cell surface U5 snRNP for the treatment of acute myeloid leukemia","fiscal_year":2026,"amount_usd":"402600","organization":"SLOAN-KETTERING INST CAN RESEARCH","source_url":"https://reporter.nih.gov/quickSearch/R01CA291796"},{"project":"R01CA291796","title":"Development of chimeric antigen receptor T cells targeting cell surface U5 snRNP for the treatment of acute myeloid leukemia","fiscal_year":2025,"amount_usd":"402600","organization":"SLOAN-KETTERING INST CAN RESEARCH","source_url":"https://reporter.nih.gov/quickSearch/R01CA291796"},{"project":"R42CA254685","title":"Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL","fiscal_year":2024,"amount_usd":"865308","organization":"ACTINIUM PHARMACEUTICALS, INC.","source_url":"https://reporter.nih.gov/quickSearch/R42CA254685"}],"source":"grants"},"contact":{"address_1":"1275 YORK AVE","city":"New York","state":"NY","zip":"100656007","phone":"212-639-2000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1831482561","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":6,"funding":2}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2020-05-08","provider_certified":"2020-05-08","collected_at":"2026-10-31T00:00:00.000Z"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}